Indraprastha Medical Corporation Ltd (INDRAMEDCO) — Board Meeting | 1 September 2026

· BSE 🟡 Notable Neutral
By StockFin Research Team AI-Assisted Analysis Source: BSE/NSE Filings
📢 Key Event
AGM scheduled for 24 September 2026 to approve financials, declare dividend, and reappoint directors.
🔄 What Changed
New independent directors appointed; board restructuring completed; dividend declared at ₹4 per share.
🔮 What's Next
Dividend payment within 30 days of AGM; record date set for 18 September 2026; CSR targets for 2026-27 include 10% energy reduction and 25% renewable energy use.
💡 Investor Takeaway
Shareholders gain clarity on dividend timing and board continuity, but ESG targets require monitoring for long-term value creation.

The filing confirms the 38th AGM of Indraprastha Medical Corporation Ltd on 24 September 2026, where shareholders will adopt FY25-26 financials, declare a ₹4 per share dividend (40% on ₹10 face value), and reappoint directors. Key resolutions include ratifying cost auditor remuneration and updating shareholder records. The company maintains a ₹3,413.44 crore market cap, ₹36.67 crore dividend payout, and ₹991.36 crore total assets. Governance updates include new independent directors (Sudhir Jalan, Harsh Pati Singhania, Vineeta Rai, Salil Singhal) and board restructuring. ESG disclosures highlight ₹326 lakh CSR spend, 10% energy reduction targets, and 84% patient satisfaction goals. No material litigation risks were identified beyond a pending Supreme Court case on free treatment policies.

📄 View Original Announcement (PDF)

About Indraprastha Medical Corporation Ltd (INDRAMEDCO)

Healthcare · Healthcare · Listed on BSE

Market Cap: ₹3,279.6 Cr P/E: 17.4 ROE: 31.5% ROCE: 43.4% Div Yield: 1.12%

View full INDRAMEDCO stock details →

📡 Get AI alerts when INDRAMEDCO files next

Free • Daily 5 PM digest • Track filings, board meetings, and corporate actions

Track INDRAMEDCO — Free

📊 More INDRAMEDCO filings

See all INDRAMEDCO filings →

Source: Stock Announcements. Analysis by StockFin.ai. For informational purposes only — not investment advice.

Editorial & Data Transparency Notice

This analysis was programmatically compiled using StockFin AI utilizing official regulatory disclosures from the BSE and NSE. Content is automatically synthesized and audited against public financial filings. StockFin.ai is an educational research platform and is NOT a SEBI-registered investment advisor or research analyst.

📡 Get AI alerts when INDRAMEDCO files new disclosures

Track INDRAMEDCO filings, board meetings, and corporate actions. Free email alerts at 5 PM.

Track INDRAMEDCO — Free

Free account · 2 AI queries/day